Navigation Links
Global Rabies Treatment May be Possible with NanoViricides Drugs

WEST HAVEN, Conn.--(BUSINESS WIRE)--May 14, 2007 - NanoViricides, Inc. (Pink Sheets: NNVC) discussed today the results of recent animal studies against rabies that were presented along with the successful BSL3 in vitro studies against a Clade 2 H5N1 virus at the 23rd Annual Symposium of the Pan American Society for Clinical Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society for Clinical Virology (PASCV): Clinical Virology Symposium)

The animal studies against rabies were conducted in Vietnam using the Challenge Standard Virus strain at a highly lethal infection level of 1,000 LD50 given directly into the brain. NanoViricides drugs based on the broad-spectrum chemicals ligand class, rabies-specific receptor peptide ligand class, as well as rabies-antibody-derived ligand class were tested in both direct intracerebral treatment as well as intraperitoneal treatment modalities. Human anti-Rabies Immunoglobulin (RIG), a commercial standard rabies treatment, was used as positive control.

A 30% survival rate with two of the nanoviricides and 20% survival rate with another two nanoviricides was found in mice treated intracerebrally, Additionally, a 20% survival rate was found with two of these four nanoviricides even on intraperitoneal treatment. All mice treated with RIG died. All of the nanoviricide drug candidates showed efficacy superior to the RIG standard, as measured by various end-points including survival and body-weight.

RIG together with rabies vaccine are given as post-exposure prophylaxis (PEP) in developed countries. However, once clinical signs are evident (prodrome phase), rabies is 100% fatal in humans. Rabies is a very important disease in developing nations. More than 50 cases of rabies infection occur in the US annually. RIG is too expensive to be used in most patients in developing nations. The Company believes that the chemical ligand-based nanoviricides can be made ine xpensively and are expected to be stable at ambient temperatures, requiring simple storage and transportation, thus allowing global use. The Company believes that it now has a candidate that can replace RIG or monoclonal antibodies for PEP usage.

"We have demonstrated that it is possible to construct highly effective antibody-based drugs within weeks, now against a second disease. We have also demonstrated that broad-spectrum, highly effective anti-viral agents that attack unrelated viruses with distinct pathologies, can be created when they share common mechanisms of binding to human cells. These achievements essentially are enabling elements for the President's Flexible Defense BioSecurity Enterprise," said Anil R. Diwan, Ph.D., President of NanoViricides, Inc.

"Our success in achieving survival of mice in a lethal infection study for the very first time raises the specter of conquering this uniformly fatal disease. This achievement has strong implications in our fight against all viral diseases," said Dr. Eugene Seymour, MD, MPH, CEO of NanoViricides, Inc.

About NanoViricides: http://www.nanoviricides.com

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

Contact

NanoViricides, Inc.
Eugene Seymour, MD MPH, CEO, 310-966-1941
info@nanoviricides.com


'"/>




Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Point of Care Strep Tests Speed Treatment, Lower Costs
5. Rapid HIV Testing Increases Possibility of Treatment
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):